PRO 140: Phase IIb start

On March 11, CytoDyn will begin an open-label, U.S. Phase IIb trial to evaluate 350 mg subcutaneous PRO 140 once weekly for up to 12 weeks as monotherapy in about 40 patients with HIV who are stable o...